Drug Trial Radar · NCT04762069
A Study of Berubicin in Adult Subjects With Recurrent Glioblastoma Multiforme
Last checked: Nov 19, 2026Latest source record: Apr 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
252
Actual
Start
May 18, 2021
Primary completion
Apr 27, 2026
Study completion Jul 15, 2026
Sponsor
- Lead sponsor
- CNS Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Worldwide Clinical Trials
- First posted
- Feb 21, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label, multicenter, randomized, parallel, 2-arm, efficacy and safety study. Patients with GBM after failure of standard first line therapy will be randomized in a 2:1 ratio to receive berubicin or lomustine for the evaluation of OS. Additional endpoints will include response and progression outcomes evaluated by a blinded central reviewer for each patient according to RANO criteria. A pre-planned, non-binding futility analysis will be performed after approximately 30 to 50% of all planned patients have completed the primary endpoint at 6 months. This review will include additional evaluation of safety as well as secondary efficacy endpoints. Enrollment will not be paused during this interim analysis.
Conditions
- Glioblastoma Multiforme, Adult
Interventions
BerubicinDrug
Berubicin HCl is a novel synthetic anthracycline with a chemical structure similar to doxorubicin HCl, a cytotoxic anthracycline topoisomerase II inhibitor isolated from cultures of Streptomyces peucetius var. caesius.
LomustineDrug
Lomustine is an anti-cancer ("antineoplastic" or "cytotoxic") chemotherapy drug. This medication is classified as an "alkylating agent.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall SurvivalTime frame: Through study completion an average of 4 years.
Locations
48 sites in 5 countries. Site status is shown where the registry gives one.
University of Arkansas
Little Rock, Arkansas
Southern California Permanente Medical Group
Los Angeles, California
University of California Irvine
Orange, California
University of Califonia San Diego Moores Cancer Center
San Diego, California
University of California San Francisco
San Francisco, California
Saint John's Cancer Institute at Providence Saint John's Health Center
Santa Monica, California
HCA Healthcare Research Institute
Englewood, Colorado
Baptist MD Anderson Cancer Center
Jacksonville, Florida
Mayo Clinic Florida
Jacksonville, Florida
Baptist Miami
Miami, Florida
Piedmont Healthcare
Atlanta, Georgia
Rush University Cancer Center
Chicago, Illinois
University of Kentucky
Lexington, Kentucky
Tulane Cancer Center Clinic
New Orleans, Louisiana
Tufts Medical Center
Boston, Massachusetts
UMass (ACC) - Hollings Cancer Center (HCC)
Worcester, Massachusetts
Mayo Clinic
Rochester, Minnesota
University of Nebraska Medical Center
Omaha, Nebraska
Hackensack Meridian Health
Hackensack, New Jersey
Rutgers University
Piscataway, New Jersey
Atlantic Healthcare
Summit, New Jersey
Roswell Park Cancer Center
Buffalo, New York
Duke University School of Medicine
Durham, North Carolina
Ohio State University
Columbus, Ohio
Providence Health
Portland, Oregon
Milton S. Hershey Medical Center
Hershey, Pennsylvania
Texas Oncology PA
Austin, Texas
Baylor Research Institute
Dallas, Texas
University of Texas Health Science Center at Houston
Houston, Texas
Huntsman Cancer Center
Salt Lake City, Utah
Swedish Medical Center
Seattle, Washington
University of Wisconsin Hospital and Clinics
Madison, Wisconsin
Hopital Pierre Wertheimer
Lyon, France
Hopital de La Timone
Marseille, France
Institut de Recherche en Cancerologie de Montpellier
Montpellier, France
Hopital Pitie-Salpetriere
Paris, France
Institut de Cancerologie de l'Ouest
Saint-Herblain, France
nstitut Universitaire du Cancer de Toulouse-
Toulouse, France
Institut de Cancerologie Gustave-Roussy
Villejuif, France
Servizio Sanitario Regionale Emilia-Romagna - Azienda USL di Bologna - Ospedale Bellaria
Bologna, Italy
Showing 40 of 48 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.